Step Pharma SAS
Step Pharma is a pioneering biotechnology company focused on developing highly selective, safe, and effective cancer treatments by targeting CTPS1, an enzyme critical for DNA and RNA synthesis in cancer cells. Their lead asset, STP938 (dencatistat), is a first-in-class, orally bioavailable CTPS1 inhibitor currently in clinical trials for blood cancers and solid tumours. The company's mission is to bring about a step change in cancer therapy by leveraging breakthrough science and genetic validation to develop targeted treatments with minimal side effects.
Industries
Nr. of Employees
small (1-50)
Step Pharma SAS
15 rue Louis et Auguste Lumière, Technoparc du Pays-de-Gex, 01630 Saint-Genis-Pouilly, France
Patents
Products
Lead oral selective CTPS1 clinical candidate (lead compound)
An orally bioavailable, selective small-molecule inhibitor of the CTPS1 target developed for oncology indications and advanced into early-phase clinical evaluation with biomarker-enriched cohorts; under clinical development for haematological malignancies, selected solid tumours and essential thrombocythaemia.
Lead oral selective CTPS1 clinical candidate (lead compound)
An orally bioavailable, selective small-molecule inhibitor of the CTPS1 target developed for oncology indications and advanced into early-phase clinical evaluation with biomarker-enriched cohorts; under clinical development for haematological malignancies, selected solid tumours and essential thrombocythaemia.
Services
Collaborative preclinical and translational research with academic and industry partners to validate target biology, generate proof-of-concept data, and explore combination strategies.
External partnerships to integrate experimental and clinical datasets using advanced statistical learning to prioritise biomarkers and inform patient selection for clinical studies.
Operational delivery of Phase I/II clinical studies including site management, investigator coordination and execution of biomarker-selected cohorts.
Collaborative preclinical and translational research with academic and industry partners to validate target biology, generate proof-of-concept data, and explore combination strategies.
External partnerships to integrate experimental and clinical datasets using advanced statistical learning to prioritise biomarkers and inform patient selection for clinical studies.
Operational delivery of Phase I/II clinical studies including site management, investigator coordination and execution of biomarker-selected cohorts.
Expertise Areas
- Targeted small-molecule discovery against CTPS1
- Medicinal chemistry and lead optimisation
- Preclinical pharmacology and toxicology
- Translational biomarker discovery and genomic patient selection
Key Technologies
- Selective small-molecule inhibitor design
- Targeted inhibition of de novo pyrimidine synthesis (CTPS1)
- In vitro antiproliferative and cytotoxicity assays
- In vivo xenograft and transplant tumour models
News & Updates
Step Pharma announced its participation in upcoming scientific and business conferences, highlighting its ongoing research and development efforts.
The European Patent Office granted patent EP3870574 to Step Pharma, covering key compounds in its portfolio of CTPS1 inhibitors, strengthening its patent protection and supporting its innovative approach to cancer treatment.
Step Pharma received a European patent (EP3870574) for key compounds in its CTPS1 inhibitor portfolio, protecting its innovative drug development efforts until at least October 2039.
Step Pharma announced its participation in upcoming scientific and business conferences, highlighting its ongoing research and development efforts.
The European Patent Office granted patent EP3870574 to Step Pharma, covering key compounds in its portfolio of CTPS1 inhibitors, strengthening its patent protection and supporting its innovative approach to cancer treatment.
Step Pharma received a European patent (EP3870574) for key compounds in its CTPS1 inhibitor portfolio, protecting its innovative drug development efforts until at least October 2039.